Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toe pressure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Toe pressure. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003387-22 Sponsor Protocol Number: Start Date*: 2007-10-07
    Sponsor Name:Pharma 2100 ApS
    Full Title: Et velkendt lægemiddels helende effekt på iskæmiske sår: et randomiseret dobbelt-blindt placebokontrolleret pilotforsøg
    Medical condition: Out-patients with ischemic (arterial) leg ulcers (systolic toe pressure: < 40 mm Hg).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005723-20 Sponsor Protocol Number: RC31/20/0445 Start Date*: 2022-02-10
    Sponsor Name:CHU de Toulouse
    Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease
    Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004128-38 Sponsor Protocol Number: 123 Start Date*: 2006-02-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Pregabalin for pain reduction in Critical Limb Ischemia
    Medical condition: Peripheral arterial disease - Critical Limb Ischemia (CLI) CLI is the end stage of peripheral arterial disease in the legs and is a onsequence of deteriorating blood flow supply to the lower limbs....
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011755-47 Sponsor Protocol Number: 2007-001 Start Date*: 2009-07-06
    Sponsor Name:Vivostat A/S
    Full Title: A feasibility study to evaluate the effect of Vivostat® Platelet Rich Fibrin (PRF®) in the treatment of diabetic foot ulcers
    Medical condition: - Diabetic foot ulcers Texas Grade I placed at or below the anchle -Non-ischaemic, non-infected ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000967-10 Sponsor Protocol Number: RC31/14/7441 Start Date*: 2019-05-24
    Sponsor Name:University Hospital Toulouse
    Full Title: Autologous transplantation of Adipose tissue derived mesenchymal Stroma/stem Cells (ASC) in patients with critical limb ischemia: a phase II study (ACellDream 2).
    Medical condition: Patients with rest pain or ischemic ulcers/gangrene of the lower limb and without option for revascularization or poor option. Or patients with with rest pain or ischemic ulcers and persistent CL...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001361-33 Sponsor Protocol Number: CYP-CLI-P2-01 Start Date*: 2020-07-27
    Sponsor Name:Cynata Therapeutics Limited
    Full Title: A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascular...
    Medical condition: Critical Limb Ischaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    21.1 100000004866 10058072 Critical limb ischaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001970-29 Sponsor Protocol Number: SP777 Start Date*: 2005-10-14
    Sponsor Name:Schwarz Pharma Deutschland GmbH
    Full Title: Multinational, prospective, randomized, double-blind, placebo-controlled, parallel groups study to assess the efficacy and safety of Prostaglandin E1 in subjects with circulatory disturbance of a limb
    Medical condition: Peripheral arterial occlusive disease (PAOD) Fontaine stage IV
    Disease: Version SOC Term Classification Code Term Level
    7.1 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-003980-21 Sponsor Protocol Number: REX-001-005 Start Date*: 2021-08-31
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placeb...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10077142 Limb ischemia LLT
    20.0 100000004866 10058069 Critical limb ischemia LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted) AT (Completed) NL (Completed) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004068-21 Sponsor Protocol Number: PADHIF00805 Start Date*: 2006-01-11
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with ...
    Medical condition: Peripheral Arterial Disease (PAD) with no or poor Chronic Critical Limb Ischemia (CLI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001800-20 Sponsor Protocol Number: PADBelch07 Start Date*: 2007-08-10
    Sponsor Name:University of Dundee
    Full Title: A randomised, placebo-controlled trial of the effect of pioglitazone on vascular endothelial function and novel biomarkers for macrovascular events in diabetics with established peripheral arterial...
    Medical condition: The study involves patients with type 2 Diabetes and Peripheral Arterial Disease.The overall objective of the research proposal is to determine the occurrence of biomarkers that typify the metaboli...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000449-15 Sponsor Protocol Number: DIONYSIUS Start Date*: 2020-12-11
    Sponsor Name:Amsterdam University Medical Centers, location AMC
    Full Title: Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
    Medical condition: Ischemic diabetic foot ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000240-34 Sponsor Protocol Number: REX-001-004 Start Date*: 2016-07-07
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: A Multicenter, Randomized, Double-Blind, Placebo Contro...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10077142 Limb ischemia LLT
    19.0 100000004866 10058069 Critical limb ischemia LLT
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) AT (Completed) NL (Ongoing) HU (Completed) PL (Completed) PT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003415-22 Sponsor Protocol Number: AP-W-CLI-2018-8 Start Date*: 2019-03-22
    Sponsor Name:Aurealis Oy
    Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers
    Medical condition: Diabetic foot ulcers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000563-69 Sponsor Protocol Number: IPCT003 Start Date*: 2021-06-04
    Sponsor Name:Ilya Pharma AB
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100 in Subjects with Diabetic Foot Ulcers
    Medical condition: Diabetic foot ulcers a systemic complication in diabetes mellitus type 1 or 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004563-31 Sponsor Protocol Number: Au18-12 Start Date*: 2022-07-25
    Sponsor Name:Centre Hospitalier Universitaire de Reims
    Full Title: Cell therapy in Critical Limb Ischemia by implantation of allogeneic umbilical cord-derived mesenchymal stem cells
    Medical condition: Evaluation of the feasibility and systemic and local tolerance of an implantation, via intramuscular route, of allogenic HB-MSC1, associated with a revascularization procedure, in patients sufferin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003399-38 Sponsor Protocol Number: NN9535-4533 Start Date*: 2020-08-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease
    Medical condition: Peripheral arterial disease Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed) NO (Completed) BE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006277-24 Sponsor Protocol Number: EFC6145 Start Date*: 2008-04-10
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI...
    Medical condition: Critical Limb Ischemia with skin lesions
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006719-20 Sponsor Protocol Number: 0431-082 Start Date*: 2009-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
    Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002414-39 Sponsor Protocol Number: MK-3102-018 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004527-67 Sponsor Protocol Number: DT-DP-DFU-CR-04 Start Date*: 2018-08-06
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing...
    Medical condition: Diabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement if indicated), Wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), tr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 14:42:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA